Anthill is a digital communications agency for the life sciences. We believe that understanding human beliefs and behaviours is the missing piece in pharma digital communications. We call it the ‘human factor’. And when applied to each stage of the development process, it results in truly empowering experiences for customers.
As a specialist life sciences digital communications agency, we work closely with global and regional teams: ensuring that every project has a strong strategy; developing the technical and creative solutions; building internal belief and support; and scaling adoption across organisations.
Early on, we believed in the potential of digital. As one of the first agencies to specialise in digital life science communications, we saw an opportunity to solve our clients’ challenges by merging powerful storytelling with the scale and personalisation that technology makes possible.
Today we partner with pharma clients around the world, delivering a wide range of services: digital marketing strategies at company-wide and brand levels; content elements and solutions for channels like eDetailing; omnichannel systems, technology integration services and even our own products like Anthill Activator.
While technology provides a huge opportunity to transform pharma communication, the full potential can only be fully realised if you take account of people – their hopes, dreams, biases, needs and beliefs. That requires deeply understanding not just the audience but everyone – internally and externally – who are involved or impacted.
That’s why we always act with The Human Factor in mind. It’s fundamental to how we think and built into every project plan. Watch the video to learn how we apply human factor thinking in our daily work.
We partner with pharma clients around the world, helping them maximize the potential of digital communications to better engage and inform healthcare professionals, patients and other stakeholders.
Anthill has worked with more than 75 life science brands, including seven of the top 30 pharmaceutical products based on revenue.